Response to Immunotherapy in MMR-deficient Localized Colon Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

June 6, 2024

Study Completion Date

June 6, 2024

Conditions
Colon Cancer
Interventions
DRUG

Pembrolizumab

One dosage of 4mg/kg (maximum of 400mg)

Trial Locations (1)

Unknown

Zealand University Hospital, Roskilde

All Listed Sponsors
collaborator

Zealand University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Vejle Hospital

OTHER

collaborator

Herlev and Gentofte Hospital

OTHER

collaborator

Bispebjerg Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Horsens Hospital

OTHER

collaborator

Randers Regional Hospital

OTHER

collaborator

Aarhus University Hospital

OTHER

lead

Camilla Qvortrup

OTHER